Steve Gavel - 13 Oct 2025 Form 4 Insider Report for Cabaletta Bio, Inc. (CABA)

Reporting relationship: CHIEF COMMERCIAL OFFICER
Issuer ticker: CABA
Reported as of: 13 Oct 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 15 Oct 2025, 16:39:25 UTC
Next SEC filing: 21 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Michael Gerard, Attorney-in-Fact

Key filing fact

Steve Gavel filed Form 4 for Cabaletta Bio, Inc. (CABA) on 15 Oct 2025.

Key facts

This page summarizes Steve Gavel's Form 4 filing for Cabaletta Bio, Inc. (CABA).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 15 Oct 2025, 16:39.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002090785 Primary reporting owner

Gavel Steve

Relationship: CHIEF COMMERCIAL OFFICER
Address: C/O CABALETTA BIO, INC., 2929 ARCH STREET, SUITE 600, PHILADELPHIA
Signature: /s/ Michael Gerard, Attorney-in-Fact
Signature date: 15 Oct 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CABA transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +275,000
Change %
Price: $0.000000
Shares after: 275,000
Date: 13 Oct 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 275,000
Exercise price: $2.49
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The stock option has been granted pursuant to the Cabaletta Bio, Inc. 2025 Inducement Plan as a material inducement to the Reporting Person's acceptance of employment with the Issuer in accordance with NASDAQ Listing Rule 5635(c)(4).

Footnote F2

25% of the shares underlying this option shall vest and become exercisable on October 13, 2026, with the remainder vesting in twelve substantially equal quarterly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.